Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,016	781.37	396.59	75.42	66.56	250.65
Revenue Growth (YoY)	42.11%	97.02%	425.83%	13.31%	-73.44%	-
Cost of Revenue	411.35	445.29	412.9	392.87	426.07	303.59
Gross Profit	605.05	336.07	-16.31	-317.45	-359.51	-52.94
Selling, General & Admin	524.64	501.05	500.82	277.16	176.77	139.4
Research & Development	-	-	-	-	-	21.38
Operating Expenses	524.64	501.05	500.82	277.16	176.77	160.78
Operating Income	80.41	-164.98	-517.12	-594.61	-536.28	-213.73
Interest Expense	-45.01	-40.39	-29.58	-32.63	-13.24	-29.94
Interest & Investment Income	13.04	12.77	20.93	8.91	0.42	4.16
Other Non Operating Income (Expenses)	-1.75	-2.17	-0.73	-0.29	-96.31	-103.53
EBT Excluding Unusual Items	46.68	-194.77	-526.5	-618.61	-645.41	-343.03
Other Unusual Items	-	-1.95	-	-32.89	-100.59	-
Pretax Income	46.68	-196.72	-526.5	-651.5	-746	-343.03
Income Tax Expense	1.7	1.16	2.13	0.67	0.35	1.85
Net Income	44.99	-197.88	-528.63	-652.17	-746.35	-344.87
Net Income to Common	44.99	-197.88	-528.63	-652.17	-746.35	-344.87
Shares Outstanding (Basic)	126	124	119	106	84	75
Shares Outstanding (Diluted)	128	124	119	106	84	75
Shares Change (YoY)	4.30%	4.40%	11.84%	25.70%	12.32%	20.79%
EPS (Basic)	0.36	-1.60	-4.45	-6.15	-8.84	-4.59
EPS (Diluted)	0.36	-1.60	-4.45	-6.15	-8.84	-4.59
Free Cash Flow	78.64	-88.27	-595.51	-515.27	-564.23	-165.91
Free Cash Flow Per Share	0.61	-0.71	-5.02	-4.86	-6.68	-2.21
Gross Margin	59.53%	43.01%	-4.11%	-	-	-21.12%
Operating Margin	7.91%	-21.11%	-130.39%	-788.38%	-805.67%	-85.27%
Profit Margin	4.43%	-25.32%	-133.29%	-864.70%	-1121.28%	-137.59%
Free Cash Flow Margin	7.74%	-11.30%	-150.16%	-683.18%	-847.66%	-66.19%
EBITDA	82.08	-163.18	-515.34	-593.06	-534.9	-213.09
EBITDA Margin	8.08%	-20.88%	-129.94%	-	-	-85.02%
D&A For EBITDA	1.68	1.8	1.78	1.55	1.38	0.64
EBIT	80.41	-164.98	-517.12	-594.61	-536.28	-213.73
EBIT Margin	7.91%	-21.11%	-130.39%	-	-	-85.27%
Revenue as Reported	1,016	781.37	396.59	75.42	66.56	250.65
Advertising Expenses	-	83.3	86.5	56.5	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.